Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Pancreatic Ductal Adenocarcinoma (PDAC) and biliary-tract cancers (BTC) often present at a late stage, and consequently patients have poor survival-outcomes. Circular RNAs (circRNAs) are non-coding RNA molecules whose role in tumourigenesis has recently been realised. They are stable, conserved and abundant, with tissue-specific expression profiles. Therefore, significant interest has arisen in their use as potential biomarkers for PDAC and BTC. High-throughput methods and more advanced bioinformatic techniques have enabled better profiling and progressed our understanding of how circRNAs may function in the competing endogenous RNA (ceRNA) network to influence the transcriptome in these cancers. Therefore, the aim of this systematic review was to describe the roles of circRNAs in PDAC and BTC, their potential as biomarkers, and their function in the wider ceRNA network in regulating microRNAs and the transcriptome. Medline, Embase, Scopus and PubMed were systematically reviewed to identify all the studies addressing circRNAs in PDAC and BTC. A total of 32 articles were included: 22 considering PDAC, 7 for Cholangiocarcinoma (CCA) and 3 for Gallbladder Cancer (GBC). There were no studies investigating Ampullary Cancer. Dysregulated circRNA expression was associated with features of malignancy in vitro, in vivo, and ex vivo. Overall, there have been very few PDAC and BTC tissues profiled for circRNA signatures. Therefore, whilst the current studies have demonstrated some of their functions in these cancers, further work is required to elucidate their potential role as cancer biomarkers in tissue, biofluids and biopsies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694172 | PMC |
| http://dx.doi.org/10.3390/cancers12113250 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Eight-Year Trends in Megestrol Acetate Prescription Among Korean Patients with Biliary-Pancreatic Cancer and Their Impact.
Nutr Cancer
May 2025
Division of Hemato-Oncology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
Background: Chemotherapy-induced anorexia and cachexia are significant challenges for patients with biliary tract cancer (BTC) and pancreatic ductal adenocarcinoma (PDAC). Megestrol acetate (MA), used to manage anorexia, has side effects and may trigger prescription cascades in cancer treatment. This study analyzed MA prescription trends and associated effects in BTC or PDAC patients.
View Article and Find Full Text PDFA RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma.
Cancer Discov
August 2025
Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York.
Unlabelled: Pharmacological inhibition of oncogenic RAS represents an attractive strategy to target pancreatic ductal adenocarcinoma (PDAC), an almost ubiquitously RAS-driven disease. However, initial responses to targeted monotherapy inhibition of active RAS can be followed by relapses, potentially driven by the persistence of drug-tolerant tumor cells. To target these "persister" cells, we investigated strategies to increase their immune visibility in mouse models of PDAC.
View Article and Find Full Text PDFClinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: a phase II trial.
Signal Transduct Target Ther
December 2024
Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Advanced biliary tract cancer (BTC) and pancreatic ductal adenocarcinoma (PDAC) have poor prognoses and limited treatment options. Here, we conducted this first-in-class phase II study to evaluate the efficacy and safety of SHR-1701, a bifunctional fusion protein targeting programmed death-ligand 1 (PD-L1) and transforming growth factor-beta (TGF-β), combined with famitinib, a multi-targeted receptor tyrosine kinase inhibitor, in patients with advanced BTC or PDAC who failed previous standard treatment (trial registration: ChiCTR2000037927). Among 51 enrolled patients, the BTC cohort showed an objective response rate (ORR) of 28% (including 2 complete responses) and a disease control rate (DCR) of 80%, with a median progression-free survival (mPFS) of 5.
View Article and Find Full Text PDFCure after surgery for hepato-pancreato-biliary cancers: A systematic review.
Dig Liver Dis
January 2025
Department of Medical and Surgical Sciences - DIMEC, Alma Mater Studiorum - University of Bologna, Bologna, Italy; Morgagni, Pierantoni Hospital, Forlì, Italy. Electronic address:
Article Synopsis
- Some patients with liver and pancreas cancers can be cured if they have surgery that aims to get rid of the cancer completely.
- Researchers studied different models to see how successful these surgeries are for different types of cancers, like liver and pancreatic cancers.
- The chance of being cured varies based on how advanced the cancer is and how well the surgery works.
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer.
Cancer Discov
November 2024
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Article Synopsis
- KRAS inhibitors are medicine that work against a type of pancreatic cancer called PDAC, but patients often develop resistance to these treatments.
- When patients with a specific mutation (KRASG12C) took certain drugs, new mutations and changes were found that helped the cancer resist the treatment.
- Using a mix of KRAS inhibitors and chemotherapy showed better results in controlling tumors in mouse models, suggesting that combining treatments might be a smarter approach for patients.